Mohammad Azab

Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin

Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

The emerging role of immune checkpoint based approaches in AML and MDS

Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)